tracking the news, one byte at a time
Freak Pulse
Category: Alzheimer’s Disease and Frontal Temporal Dementia
-
Research Breakthroughs and Scientific, Scientists reversed memory loss, and more.
Research Breakthroughs and Scientific Discoveries this week: Inserm and University of Bordeaux researchers have established a direct causal link between mitochondrial; and The Dominantly Inherited Alzheimer Network (DIAN), a critical…
-
Diagnostic Advances and Biomarkers, Alzheimer s 2026 Breakthrough, and more.
Diagnostic Advances and Biomarkers this week: In 2026, Alzheimer’s disease diagnosis and treatment are undergoing a fundamental shift; and Amsterdam UMC researchers have validated a novel cerebrospinal fluid biomarker, AcTau174, which can…
-
New Drug Trials and Approvals, Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise, and more.
New Drug Trials and Approvals this week: Biogen’s Phase 2 CELIA study of its tau-targeting antisense oligonucleotide diranersen (BIIB080) showed a clinically; and Biogen has announced topline results from the 18-month Phase 2 CELIA study…
-
Roundup: FTD Treatment & Genetics, Black Box Warnings for Antipsychotics, and more.
Frontotemporal Signals this week: A clinical review outlines the severe limitations and risks of psychotropic medication for managing neuropsychiatric; and This matters for Alzheimer’s Disease and Frontal Temporal Dementia because it…
-
Research Reviews and Treatment Debates, 2026 Alzheimer’s disease facts figures – PMC, and more.
Research Reviews and Treatment Debates this week: The 2026 Alzheimer’s disease facts and figures report consolidates the state of early detection and treatment; and Harvard researchers Bruce Yankner, Sandeep Robert Datta, and Chenghua Gu…
-
Blood Tests and Biomarkers for Early, Alzheimer s 2026 Breakthrough, and more.
Blood Tests and Biomarkers for Early Detection this week: In 2026, Alzheimer’s disease management is being reshaped by the clinical deployment of high-precision blood; and Amsterdam UMC researchers have identified a novel cerebrospinal…
-
New Alzheimer’s Drug Trials and, Annovis Publishes Phase 2/3, and more.
New Alzheimer’s Drug Trials and Clinical Results this week: Annovis Bio has published peer-reviewed Phase 2/3 results for its oral Alzheimer’s candidate, buntanetap, in NPJ; and Annovis Bio has published peer-reviewed Phase 2/3 data for…
-
Roundup: Blood Signals, Blood test has potential detect earliest signals Alzheimer’s, and more.
Blood Signals this week: This matters for Alzheimer’s Disease and Frontal Temporal Dementia because it gives a concrete current signal to; and This matters for Alzheimer’s Disease and Frontal Temporal Dementia because it gives a concrete…
-
Roundup: Cervomed Signals, CervoMed Announces Data 2026 AAN Annual Meeting, and more.
Cervomed Signals this week: This matters for Alzheimer’s Disease and Frontal Temporal Dementia because it gives a concrete current signal to; and This matters for Alzheimer’s Disease and Frontal Temporal Dementia because it gives a…
-
Roundup: Policy, FDA approves much-debated Alzheimer’s drug panned experts, and more.
Policy, Courts, And Regulation this week: The FDA has granted accelerated approval to Biogen and Eisai’s aducanumab (Aduhelm) for Alzheimer’s disease, marking; and This matters for Alzheimer’s Disease and Frontal Temporal Dementia because…